Asset / Drug

Cardiology

Drug and asset intelligence for Cardiology with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Stage: Development stage unavailable

Recent signals(5)

ClinicalJune 18, 2026

Digital Management Improves Outcomes in Early Cardiogenic Shock Patients

A clinical trial involving 472 patients with early-stage cardiogenic shock evaluated the HeartMed-HF digital management system, showing potential benefits over standard discharge guidance.

ClinicalJune 18, 2026

Study on Optimizing CRT Lead Placement for Non-LBBB Patients Using Advanced Imaging Techniques

The RESYNC-PETCT study aims to improve CRT response in heart failure patients with non-LBBB or narrow LBBB patterns through advanced imaging guidance.

ClinicalJune 17, 2026

NORM-HF Study to Evaluate FIRE1 NORM™ System in Heart Failure Management

The NORM-HF study aims to show that the FIRE1 NORM™ System is superior to standard care in managing heart failure.

ClinicalJune 2, 2026

Trial on Pulmonary Artery Catheters in Cardiac Surgery Aims to Compare Recovery Outcomes

This clinical trial will evaluate the impact of avoiding pulmonary artery catheters on recovery outcomes in cardiac surgery patients.

RegulatoryJune 1, 2026

AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class Treatment

Baxfendy has been approved in the US as the first and only aldosterone synthase inhibitor for adults with hypertension, showing a significant reduction in systolic blood pressure.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Therapeutic areas

Surgical Intervention →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.